Among healthy controls, NAFLD and NASH patients, the expression levels of HSP90β, but not HSP90α, was positively correlated with disease progression (Fig. 2m–o). This evidence concerns the gene HSP90AA1 and metabolic dysfunction-associated steatotic liver disease.